Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paroxetine + zolpidem
- Development stage
- Phase 1
- Lead developer
- Almatica Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Paroxetine + zolpidem is a combination of two pharmaceutical drugs used together, primarily studied for the treatment of primary insomnia. Paroxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant, while zolpidem is a non-benzodiazepine hypnotic agent that acts as an agonist at the gamma-aminobutyric acid (GABA) A receptor complex. The combination has been shown to be more effective than zolpidem alone in improving sleep maintenance and reducing early morning awakenings in patients with primary insomnia. However, combining these agents can result in additive central nervous system depression and impairment of psychomotor skills[1][2].
02
Targets
SERT (Sodium-dependent serotonin transporter)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)
Beyond the preview
Go deeper on paroxetine + zolpidem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paroxetine + zolpidem.